Scientific Industries (SCND) Registration Filing summary

Company overview and business model

• Designs, manufactures, and markets benchtop laboratory equipment and bioprocessing systems for research use in universities, pharma, and industry.

• Operates two segments: Benchtop Laboratory Equipment (mixers, shakers, scales, pill counters) and Bioprocessing Systems (smart sensors, analytics, software).

• Bioprocessing segment targets growth in the synthetic biology market, with recent product launches and acquisitions to expand capabilities.

• Products are distributed via laboratory equipment distributors, online, and direct sales.

Financial performance and metrics

• Net loss of $1.78M for Q1 2025, $6.45M for 2024, and $9.09M for 2023; accumulated deficit of $35.7M as of March 31, 2025.

• Net revenues for 2024 were $10.7M, down 3.6% from 2023; gross profit margin decreased to 44.2% in 2024.

• Benchtop segment remains profitable, but bioprocessing expansion drives ongoing losses.

• Cash and equivalents were $587,900 at end of 2024; negative cash flow from operations of $3.68M in 2024.

• Management expresses substantial doubt about ability to continue as a going concern without additional capital.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling stockholders; company will receive proceeds only from warrant exercises.

• Any proceeds from warrant exercises will be used for ordinary working capital needs.

• No dividends anticipated; earnings to be retained for business development and expansion.